Request for Leniency from CytoDyn Shareholders for Dr Nader Pourhassan, PhD
Request for Leniency from CytoDyn Shareholders for Dr Nader Pourhassan, PhD
The Issue
We, the undersigned, current shareholders of CytoDyn Inc (Vancouver, WA), respectfully request leniency in the sentencing of our former CEO, Dr Nader Pourhassan. We take no issue with the decisions reached by the jury of his peers, but as shareholders, we would like to make the court aware of the following:
1. We don't believe Dr Pourhassan acted with deliberate malfeasance or malice aforethought. Instead, as witnessed by us during his tenure as our CEO, we believe it was his enthusiasm, passion, and intensity of belief in the safety and efficacy of our molecule (Leronlimab, aka PRO 140) that motivated his premature statements and subsequent actions.
2. Given the time frame of Dr Pourhassan's premature statements and subsequent actions -the initial phase of the Covid 19 pandemic - we believe the pressure to "get something approved ASAP" further fueled his frustration with our CRO (in completing the BLA) to further cloud his judgement.
3. He was wrong in what he said and did re: the BLA submission (implying it was properly formatted and complete), but NOT, we believe, because he wanted to make some short-term profit. Passion and enthusiasm, frustration and shareholder pressure to get something approved - we believe these were the primary drivers of his premature statements and subsequent actions.
4. We believe what he did for shareholders "behind the scenes" speaks much more to his character than his statements and actions re: the BLA submission. Dr Pourhassan has, on many occasions, personally picked up the phone and spoken directly to shareholders (and non-shareholders) who had loved ones in the last days of life. No existing treatment had worked for them, and Leronlimab was their last hope. And when he didn't have to, when he was under no obligation to do so, Nader came through, often and repeatedly, to minimize all delays and provide the necessary doses of Leronlimab. Dr Pourhassan went above and beyond what he had to do, and his quick and definitive actions saved lives.
5. In short, we, the undersigned shareholders of CytoDyn Inc, request that Dr Pourhassan's sentencing be reduced to the absolute minimum. We believe he has proven himself to be a good and decent man, and during a time of great pressure (the initial phase of Covid 19), his better judgement failed to rein in his passion and enthusiasm for what we, the shareholders, truly believe to be a near-miracle drug. We do not believe we were permanently financially harmed by his statements or actions, and we believe he has suffered enough with the loss of his reputation and employment. With all humility and sincerity, we, the shareholders of CytoDyn, respectfully request that Dr Nader Pourhassan be returned to his family and society at the earliest possible date.
6. Finally, here are a few links (more available upon request) that give both context and support to Dr Pourhassan's enthusiasm regarding the monoclonal antibody that safely and uniquely targets the CCR5 receptor:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7665416/
https://www.cbsnews.com/losangeles/news/covid-19-survivor-coronavirus-experimental-drug-leronlimab/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/
The Issue
We, the undersigned, current shareholders of CytoDyn Inc (Vancouver, WA), respectfully request leniency in the sentencing of our former CEO, Dr Nader Pourhassan. We take no issue with the decisions reached by the jury of his peers, but as shareholders, we would like to make the court aware of the following:
1. We don't believe Dr Pourhassan acted with deliberate malfeasance or malice aforethought. Instead, as witnessed by us during his tenure as our CEO, we believe it was his enthusiasm, passion, and intensity of belief in the safety and efficacy of our molecule (Leronlimab, aka PRO 140) that motivated his premature statements and subsequent actions.
2. Given the time frame of Dr Pourhassan's premature statements and subsequent actions -the initial phase of the Covid 19 pandemic - we believe the pressure to "get something approved ASAP" further fueled his frustration with our CRO (in completing the BLA) to further cloud his judgement.
3. He was wrong in what he said and did re: the BLA submission (implying it was properly formatted and complete), but NOT, we believe, because he wanted to make some short-term profit. Passion and enthusiasm, frustration and shareholder pressure to get something approved - we believe these were the primary drivers of his premature statements and subsequent actions.
4. We believe what he did for shareholders "behind the scenes" speaks much more to his character than his statements and actions re: the BLA submission. Dr Pourhassan has, on many occasions, personally picked up the phone and spoken directly to shareholders (and non-shareholders) who had loved ones in the last days of life. No existing treatment had worked for them, and Leronlimab was their last hope. And when he didn't have to, when he was under no obligation to do so, Nader came through, often and repeatedly, to minimize all delays and provide the necessary doses of Leronlimab. Dr Pourhassan went above and beyond what he had to do, and his quick and definitive actions saved lives.
5. In short, we, the undersigned shareholders of CytoDyn Inc, request that Dr Pourhassan's sentencing be reduced to the absolute minimum. We believe he has proven himself to be a good and decent man, and during a time of great pressure (the initial phase of Covid 19), his better judgement failed to rein in his passion and enthusiasm for what we, the shareholders, truly believe to be a near-miracle drug. We do not believe we were permanently financially harmed by his statements or actions, and we believe he has suffered enough with the loss of his reputation and employment. With all humility and sincerity, we, the shareholders of CytoDyn, respectfully request that Dr Nader Pourhassan be returned to his family and society at the earliest possible date.
6. Finally, here are a few links (more available upon request) that give both context and support to Dr Pourhassan's enthusiasm regarding the monoclonal antibody that safely and uniquely targets the CCR5 receptor:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7665416/
https://www.cbsnews.com/losangeles/news/covid-19-survivor-coronavirus-experimental-drug-leronlimab/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/
Victory
Share this petition
Supporter Voices
Petition Updates
Share this petition
Petition created on March 1, 2025